MYC and Miyoshi myopathy: Our studies showed synergy between EZM2302 and IMiDs against MM cells (Figures 1A–1E and S2A–S2E), as well as IKZF3 and MYC to be more downregulated by the combination of EZM2302 and pomalidomide as compared with single agents (Figures 1G and S3A–S3C).